Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the safety and efficacy of FTY720 combined with cyclosporine and corticosteroids in patients receiving a kidney transplant.

• Phase: Phase 2

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Collaborator: Mitsubishi Tanabe Pharma Corporation
• Treatments: Fingolimod Hydrochloride

Criteria

Inclusion Criteria

• Patients who have completed the 12 Month visit of the Core trial either on or off study drug.

• Female capable of becoming pregnant are required to have a medically approved method of birth control until 3 Month after study medication was stopped.

Exclusion Criteria

• None